Long-term Extension Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia

• ClinicalTrials.gov Identifier: NCT01614912
• Recruitment Status: Completed
• First Posted: June 8, 2012
• Results First Posted: October 19, 2018
• Last Update Posted: October 19, 2018
• Sponsor: Sumitomo Dainippon Pharma Co., Ltd.
• Information provided by (Responsible Party): Sumitomo Dainippon Pharma Co., Ltd.

Study Description

Brief Summary:

The study evaluates the long term safety and efficacy of SM-13496 in patients with schizophrenia.

Condition or disease	Intervention/treatment	Phase
Schizophrenia	Drug: SM-13496	Phase 3

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 284 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Long-term Extension Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia <Phase 3>
• Study Start Date: August 2012
• Actual Primary Completion Date: May 2015
• Actual Study Completion Date: May 2015

Arms and Interventions

Arm	Intervention/treatment
Experimental: SM-13496	Drug: SM-13496; 40 or 80 mg once daily orally

Outcome Measures

Primary Outcome Measures :

1. Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at LOCF Endpoint [ Time Frame: DB baseline and up to 32 weeks (LOCF endpoint) ]
   The PANSS is an interview-based measure of the severity of psychopathology in adults with psychotic disorders. The measure is comprised of 30 items and three subscales: the Positive subscale contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness/persecution, and hostility; the Negative subscale contains seven questions to assess blunted effect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of motivation, and similar symptoms; and the General Psychopathology subscale addresses other symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS total score is the sum of all 30 items and ranges from 30 through 210. A higher score is associated with greater illness severity.

Secondary Outcome Measures :

1. Change From Baseline in the Clinical Global Impression - Severity of Illness (CGI-S) Score at LOCF Endpoint [ Time Frame: DB baseline and up to 32 weeks (LOCF endpoint) ]

   CGI-S is a clinician-rated assessment of the participant's current disease state on a 7-point scale, where a higher score is associated with greater severity of the disease.

   Baseline in the prior study (D1001056, double-blind [DB] baseline) was defined as baseline of the prior study. Baseline in the present study (D1001057, extension [EXT] baseline) was defined as Week 6 in the prior study.

   The last post-baseline visit data collected during the study treatment of the present study were carried forward and defined as the last observation carried forward (LOCF) endpoint.

2. Change From Baseline in PANSS Positive Subscale Score at LOCF Endpoint [ Time Frame: DB baseline and up to 32 weeks (LOCF endpoint) ]
   The PANSS is comprised of 30 items and three subscales. The Positive subscale contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS Positive subscale score is the sum of all 7 items and ranges from 7 through 49. A higher score is associated with greater illness severity.
3. Change From Baseline in PANSS Negative Subscale Score at LOCF Endpoint [ Time Frame: DB baseline and up to 32 weeks (LOCF endpoint) ]
   The PANSS is comprised of 30 items and three subscales. The Negative subscale contains seven questions to assess blunted effect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of motivation, and similar symptoms. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS Negative subscale score is the sum of all 7 items and ranges from 7 through 49. A higher score is associated with greater illness severity.
4. Change From Baseline in PANSS General Psychopathology Subscale Score at LOCF Endpoint [ Time Frame: DB baseline and up to 32 weeks (LOCF endpoint) ]
   The PANSS is comprised of 30 items and three subscales. The General Psychopathology subscale addresses other 16 symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS General Psychopathology subscale score is the sum of all 16 items and ranges from 16 through 112. A higher score is associated with greater illness severity.
5. Proportion of Participants With Treatment-Emergent Adverse Events (TEAEs) [ Time Frame: EXT baseline and up to 26 weeks ]
   Proportion of participants with treatment-emergent adverse events. An adverse event was defined as any untoward medical occurrence in a patient treated with a medicinal (investigational) product and which did not necessarily have a causal relationship with this treatment. Treatment-emergent adverse events are defined as adverse events with a start date on or after the date of initial administration of study drug in the present study through the end of follow-up or adverse events occurring before the date of initial administration of study drug in the present study and worsening during the study treatment in the present study.
6. Proportion of Participants With TEAEs Leading to Discontinuation [ Time Frame: EXT baseline and up to 26 weeks ]
7. Proportion of Participants With Treatment-emergent Serious Adverse Events (SAEs) [ Time Frame: EXT baseline and up to 26 weeks ]
   Proportion of participants with treatment-emergent adverse events. A serious adverse event was defined as an AE that met one or more of the following criteria: Resulted in death; Was life-threatening (i.e., a patient was at immediate risk of death at the time of the event, not an event where occurrence in a more severe form might have caused death); Required hospitalization or prolongation of existing hospitalization; Resulted in persistent or significant disability or incapacity; Was a congenital anomaly or birth defect; Was an important medical event that might jeopardize the patient or might require medical intervention to prevent one of the outcomes listed above.

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 74 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Patients who are considered by the investigator eligible for the present study with no significant safety concerns
• Patients who are fully informed of and understand the objectives, procedures, and possible benefits and risks of the study and who provide written voluntarily consent to participate in the study

Exclusion Criteria:

• Patients who are planning pregnancy for the expected duration of the study
• Patients who are otherwise considered ineligible for the study by the investigator

Contacts and Locations

Locations

Japan

69 Sites

Tokyo, Etc, Japan

Korea, Republic of

22 Sites

Seoul, Etc, Korea, Republic of

Malaysia

10 Sites

Kuala Lumpur, Etc, Malaysia

Taiwan

14Sites

Taipei, Etc, Taiwan

Sponsors and Collaborators

Sumitomo Dainippon Pharma Co., Ltd.

More Information

• Responsible Party: Sumitomo Dainippon Pharma Co., Ltd.
• ClinicalTrials.gov Identifier: NCT01614912
• Other Study ID Numbers: D1001057; JapicCTI-121860 ( Registry Identifier: JAPIC Clinical Traials Information )
• First Posted: June 8, 2012
• Results First Posted: October 19, 2018
• Last Update Posted: October 19, 2018
• Last Verified: July 2017

Additional relevant MeSH terms:

Schizophrenia; Schizophrenia Spectrum and Other Psychotic Disorders; Mental Disorders; Lurasidone Hydrochloride; Antipsychotic Agents; Tranquilizing Agents; Central Nervous System Depressants; Physiological Effects of Drugs; Psychotropic Drugs; Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Adrenergic Agents; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Serotonin Agents; Dopamine D2 Receptor Antagonists; Dopamine Antagonists; Dopamine Agents